SynthesisCancer2006
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
Synthesis in Cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Interferon alpha for the adjuvant treatment of cutaneous melanoma.The Cochrane database of systematic reviews · 2013Pooled it
- Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2026Review
- Review
- Spin in Abstracts of Systematic Reviews and Meta-analyses of Melanoma Therapies: Cross-sectional Analysis.JMIR dermatology · 2022Article
- Evaluation of Chest Radiographs and Laboratory Testing during Melanoma Staging Procedures.The American surgeon · 2019Article
- Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.Frontiers in immunology · 2018Review
- Review
- Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.Pathology oncology research : POR · 2014Article
- Primary malignant melanoma of the breast: A case report and review of the literature.Oncology letters · 2014Article
- The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model.Cancer biotherapy & radiopharmaceuticals · 2013Article
- Multimodality treatment in the management of anorectal melanoma: a case report and review of the literature.The Eurasian journal of medicine · 2011Article
- Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.Expert opinion on pharmacotherapy · 2011Review
- A new era in the treatment of melanoma: from biology to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011Review
- Racial differences in survival after surgical treatment for melanoma.Annals of surgical oncology · 2011Article
- The evolving role of radiation therapy in the management of malignant melanoma.International journal of radiation oncology, biology, physics · 2011Review
- Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.Cancer chemotherapy and pharmacology · 2011Article
- Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.The American journal of pathology · 2011Article
- Socioeconomic status and chemotherapy use for melanoma in older people.Canadian journal on aging = La revue canadienne du vieillissement · 2011Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors examined the role of systemic adjuvant therapy in patients with high-risk, resected, primary melanoma. Outcomes of interest included overall survival, disease-free survival, adverse effects, and quality of life. A systematic review of the literature was conducted to locate randomized controlled trials, practice guidelines, meta-analyses, and reviews published between 1980 and 2004. Thirty-seven randomized controlled trials, 2 meta-analyses, and 1 systematic review were identified that investigated interferon, levamisole, vaccine, or chemotherapy as adjuvant therapy. For high-dose interferon-alpha, the results from 3 randomized trials conducted by the Eastern Cooperative Oncology Group were pooled, and a meta-analysis of 2-year death rates yielded a risk ratio of 0.85 (95% confidence interval, 0.73-0.99; P = .03). Five randomized trials comparing low-dose interferon-alpha with observation only after surgery did not detect a statistically significant improvement in overall survival. A meta-analysis of 4 levamisole trials did not demonstrate a significant survival benefit for levamisole over control; similarly, no survival benefit was demonstrated by data from randomized controlled trials with vaccines (9 trials) or with chemotherapy (10 trials). In this review of the available literature, no systemic adjuvant therapy was identified that conferred a significant overall survival benefit in patients with high-risk, resected, primary melanoma. However, high-dose interferon should be considered in the treatment of these patients, because such therapy is associated with a significant improvement in disease-free survival and a reduction in 2-year mortality. Until the results of ongoing trials are available, the authors could not state with confidence whether such therapy benefits patients with microscopically detected, sentinel lymph node-positive disease.
Indexed as
Identifiers
16511841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.